canertinib has been researched along with pd168393 in 4 studies
| Studies (canertinib) | Trials (canertinib) | Recent Studies (post-2010) (canertinib) | Studies (pd168393) | Trials (pd168393) | Recent Studies (post-2010) (pd168393) |
|---|---|---|---|---|---|
| 124 | 9 | 65 | 61 | 0 | 33 |
| Protein | Taxonomy | canertinib (IC50) | pd168393 (IC50) |
|---|---|---|---|
| Proto-oncogene tyrosine-protein kinase Src | Gallus gallus (chicken) | 1.0702 | |
| Epidermal growth factor receptor | Homo sapiens (human) | 0.0143 | |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | 0.0334 | |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | 0.1543 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.073 | |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | 0.0011 | |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | 5.47 | |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | 0.5757 | |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | 3.14 | |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | 5.83 | |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | 0.0047 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (75.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, OH; Denny, WA; Elliott, WL; Greis, KD; Lipka, E; Loo, JA; Rewcastle, GW; Reyner, EL; Showalter, HD; Smaill, JB; Vincent, PW | 1 |
| Bridges, AJ; Denny, WA; Elliott, WL; Fry, DW; McNamara, DJ; Nelson, JM; Roberts, BJ; Sherwood, V; Showalter, HD; Smaill, JB; Vincent, PW; Zhou, H | 1 |
| Balk, SP; Didonato, M; Flatauer, L; Gray, NS; Hur, W; Jiang, X; Kim, S; Larson, B; Mason, DE; Nagle, A; Peters, EC; Suzuki, M; Valente, D; Velentza, A; Warmuth, M; Zagorska, A; Zhang, J | 1 |
| Barf, T; Kaptein, A | 1 |
1 review(s) available for canertinib and pd168393
| Article | Year |
|---|---|
Irreversible protein kinase inhibitors: balancing the benefits and risks.
Topics: Animals; Cell Line; Humans; Protein Kinase Inhibitors; Protein Kinases; Risk; Structure-Activity Relationship; Time Factors | 2012 |
3 other study(ies) available for canertinib and pd168393
| Article | Year |
|---|---|
Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6-acrylamides bearing additional solubilizing functions.
Topics: Acrylamides; Animals; Antineoplastic Agents; Biological Transport; Caco-2 Cells; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Humans; Mice; Mice, Nude; Morpholines; Neoplasm Transplantation; Phosphorylation; Pyrimidines; Quinazolines; Receptor, ErbB-2; Solubility; Spectrometry, Mass, Electrospray Ionization; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
Tyrosine kinase inhibitors. 18. 6-Substituted 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Inhibitory Concentration 50; Mice; Phosphorylation; Pyrimidines; Quinazolines; Solubility; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Clinical stage EGFR inhibitors irreversibly alkylate Bmx kinase.
Topics: Animals; Cysteine; ErbB Receptors; Mice; Molecular Structure; Morpholines; Protein-Tyrosine Kinases; Quinazolines; Sequence Homology, Amino Acid | 2008 |